Sharescart Research Club logo ×
Screener Research Unlisted Startup Funding New IPO New

  • Home
  • /
  • Evoq Remedies
Join Channel
Consolidated Standalone

EVOQ Remedies

₹10.1 -0 | 0.2%

Market Cap ₹14 Cr.

Stock P/E

P/B 0.6

Current Price ₹10.1

Book Value ₹ 18.2

Face Value 10

52W High ₹19.4

Dividend Yield 0%

52W Low ₹ 8.5

Edit Ratio

EVOQ Remedies Research see more...

Overview Inc. Year: 2010Industry: Trading

Evoq Remedies Ltd engages inside the marketing, buying and selling, and distribution of prescription drugs raw material and chemicals in India. It trades in excipients, nutraceuticals, pellets, solvents, sweeteners, vitamins, amino acids, bulk tablets, dairy products, and active pharmaceutical components. The agency turned into integrated in 2010 and is primarily based in Ahmedabad, India.

Read More..

EVOQ Remedies Share Price

New

₹ | |

Volume
Price

Quarterly Price

Quarterly Monthly
Show Value Show %

Peer Comparison

EVOQ Remedies Quarterly Results

#(Fig in Cr.)
Net Sales
Other Income
Total Income
Total Expenditure
Operating Profit
Interest
Depreciation
Exceptional Income / Expenses
Profit Before Tax
Provision for Tax
Profit After Tax
Adjustments
Profit After Adjustments
Adjusted Earnings Per Share

EVOQ Remedies Profit & Loss

#(Fig in Cr.) Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 TTM
Net Sales 3 9 10 17 20
Other Income 0 0 0 0 6
Total Income 3 9 10 17 26
Total Expenditure 3 9 9 15 24
Operating Profit 0 0 1 1 2
Interest 0 0 0 0 0
Depreciation 0 0 0 0 0
Exceptional Income / Expenses 0 0 0 0 0
Profit Before Tax 0 0 1 1 2
Provision for Tax 0 0 0 0 1
Profit After Tax 0 0 1 1 2
Adjustments 0 0 0 0 0
Profit After Adjustments 0 0 1 1 2
Adjusted Earnings Per Share 0 0 10.1 0.8 1.2

Growth Rates

# 1 Year 3 Year 5 Year 10 Year
Sales CAGR 18% 30% 0% 0%
Operating Profit CAGR 100% 0% 0% 0%
PAT CAGR 100% 0% 0% 0%
# 1 Year 3 Year 5 Year 10 Year
Share Price CAGR -25% NA% NA% NA%
ROE Average 7% 68% 51% 51%
ROCE Average 7% 88% 67% 67%

EVOQ Remedies Balance Sheet

#(Fig in Cr.) Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Shareholder's Funds 0 0 1 23 25
Minority's Interest 0 0 0 0 0
Borrowings 0 0 0 0 0
Other Non-Current Liabilities 0 0 0 0 0
Total Current Liabilities 2 6 7 10 10
Total Liabilities 2 6 8 33 35
Fixed Assets 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Total Current Assets 2 6 8 33 35
Total Assets 2 6 8 33 35

EVOQ Remedies Cash Flow

#(Fig in Cr.) Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Opening Cash & Cash Equivalents 0 0 0 0 3
Cash Flow from Operating Activities 0 -0 0 -26 -4
Cash Flow from Investing Activities 0 0 0 0 -0
Cash Flow from Financing Activities 0 0 0 29 1
Net Cash Inflow / Outflow 0 -0 0 3 -3
Closing Cash & Cash Equivalent 0 0 0 3 0

EVOQ Remedies Ratios

# Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Earnings Per Share (Rs) 0 0 10.08 0.8 1.19
CEPS(Rs) 0.16 0 10.08 0.8 1.19
DPS(Rs) 0 0 0 0 0
Book NAV/Share(Rs) 0 0 10.47 17.03 18.22
Core EBITDA Margin(%) 0.5 0.01 9.52 8.72 -18.31
EBIT Margin(%) 0.5 0.01 9.52 8.72 11.21
Pre Tax Margin(%) 0.49 0.01 9.52 8.69 11.2
PAT Margin (%) 0.34 0 7.14 6.5 7.94
Cash Profit Margin (%) 0.34 0 7.14 6.5 7.96
ROA(%) 0.52 0.01 10.45 5.27 4.75
ROE(%) 49.78 1.34 186.89 9.13 6.75
ROCE(%) 68.94 2.69 246.9 9.12 6.96
Receivable days 137.91 119.61 210.34 350.51 381.41
Inventory Days 3.37 1.82 3.85 10.17 25.21
Payable days 239.62 156.19 288.3 105.88 6.35
PER(x) 0 0 0 28.17 10.91
Price/Book(x) 0 0 0 1.33 0.71
Dividend Yield(%) 0 0 0 0 0
EV/Net Sales(x) -0 0 -0 2.13 1.33
EV/Core EBITDA(x) -0.47 19.71 -0.02 24.47 11.83
Net Sales Growth(%) 0 179.14 10.5 67.42 21.49
EBIT Growth(%) 0 -95.68 0 53.34 56.24
PAT Growth(%) 0 -97.3 0 52.53 48.38
EPS Growth(%) 0 0 0 -92.04 48.39
Debt/Equity(x) 0.05 0.27 0 0.35 0.39
Current Ratio(x) 1.01 1.01 1.1 3.28 3.45
Quick Ratio(x) 1 0.99 1.08 3.2 3.25
Interest Cover(x) 81 3.5 5225.15 318.04 1758.31
Total Debt/Mcap(x) 0 0 0 0.27 0.54

EVOQ Remedies Shareholding Pattern

# Mar 2022 Sep 2022 Mar 2023 Sep 2023 Mar 2024
Promoter 73.53 73.53 73.53 73.53 20.53
FII 0 0 0 0 0
DII 0 0 0 0 0
Public 26.47 26.47 26.47 26.47 79.47
Others 0 0 0 0 0
Total 100 100 100 100 100

Pros

  • Stock is trading at 0.6 times its book value
  • Company has a good return on equity (ROE) track record: 3 Years ROE 68%
  • Debtor days have improved from 105.88 to 6.35days.
  • Company is almost debt free.

Cons

  • Promoter holding is low: 20.53%.
  • Earnings include an other income of Rs. 6 Cr.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

EVOQ Remedies News

Top Unlisted Companies & InstaBuy Companies

Sell or Purchase Share (Tentative Price)

IPO

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

You May Also Know About

Unlisted Shares Pre-IPO Shares ESOP Shares Delisted Shares

Please Login!

Click to Login
OR
Get free Account

Error!